Metal binding is required for tachpyridine-induced G2/M arrest
Treatment . | G0/G1, % . | S, % . | G2/M, % . |
|---|---|---|---|
| Untreated | 54 ± 4 | 31 ± 3 | 15 ± 1 |
| 7.5 μM (N-Me)3 tachpyridine | 50 ± 2 | 37 ± 4 | 13 ± 3 |
| 10 μM (N-Me)3 tachpyridine | 54 ± 4 | 31 ± 3 | 16 ± 1 |
| 7.5 μM tachpyridine | 36 ± 4 | 20 ± 5 | 45 ± 1 |
| 10 μM tachpyridine | 34 ± 3 | 20 ± 2 | 47 ± 2 |
Treatment . | G0/G1, % . | S, % . | G2/M, % . |
|---|---|---|---|
| Untreated | 54 ± 4 | 31 ± 3 | 15 ± 1 |
| 7.5 μM (N-Me)3 tachpyridine | 50 ± 2 | 37 ± 4 | 13 ± 3 |
| 10 μM (N-Me)3 tachpyridine | 54 ± 4 | 31 ± 3 | 16 ± 1 |
| 7.5 μM tachpyridine | 36 ± 4 | 20 ± 5 | 45 ± 1 |
| 10 μM tachpyridine | 34 ± 3 | 20 ± 2 | 47 ± 2 |
HeLa cells were treated with 7.5 μM and 10 μM tachpyridine or (N-Me)3 tachpyridine for 24 hours, and cell-cycle distribution was determined by flow cytometry. Means and standard deviations of triplicate determinations are shown.